Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration

dc.contributor.authorLau, Colleen
dc.contributor.authorSheridan, Sarah
dc.contributor.authorRyan, Stephanie
dc.contributor.authorRoineau, Maureen
dc.contributor.authorAndreosso, Athena
dc.contributor.authorFuimaono, Saipale D
dc.contributor.authorTufa, Joseph
dc.contributor.authorGraves, Patricia
dc.date.accessioned2021-06-06T23:34:39Z
dc.date.available2021-06-06T23:34:39Z
dc.date.issued2017
dc.date.updated2020-11-23T10:24:52Z
dc.description.abstractThe Global Programme to Eliminate Lymphatic Filariasis (LF) aims to eliminate the disease as a public health problem by 2020 by conducting mass drug administration (MDA) and controlling morbidity. Once elimination targets have been reached, surveillance is critical for ensuring that programmatic gains are sustained, and challenges include timely identification of residual areas of transmission. WHO guidelines encourage cost-efficient surveillance, such as integration with other population-based surveys. In American Samoa, where LF is caused by Wuchereria bancrofti, and Aedes polynesiensis is the main vector, the LF elimination program has made significant progress. Seven rounds of MDA (albendazole and diethycarbamazine) were completed from 2000 to 2006, and Transmission Assessment Surveys were passed in 2010/2011 and 2015. However, a seroprevalence study using an adult serum bank collected in 2010 detected two potential residual foci of transmission, with Og4C3 antigen (Ag) prevalence of 30.8% and 15.6%. We conducted a follow up study in 2014 to verify if transmission was truly occurring by comparing seroprevalence between residents of suspected hotspots and residents of other villages. In adults from non-hotspot villages (N = 602), seroprevalence of Ag (ICT or Og4C3), Bm14 antibody (Ab) and Wb123 Ab were 1.2% (95% CI 0.6–2.6%), 9.6% (95% CI 7.5%-12.3%), and 10.5% (95% CI 7.6–14.3%), respectively. Comparatively, adult residents of Fagali’i (N = 38) had significantly higher seroprevalence of Ag (26.9%, 95% CI 17.3–39.4%), Bm14 Ab (43.4%, 95% CI 32.4–55.0%), and Wb123 Ab 55.2% (95% CI 39.6–69.8%). Adult residents of Ili’ili/Vaitogi/Futiga (N = 113) also had higher prevalence of Ag and Ab, but differences were not statistically significant. The presence of transmission was demonstrated by 1.1% Ag prevalence (95% CI 0.2% to 3.1%) in 283 children aged 7–13 years who lived in one of the suspected hotspots; and microfilaraemia in four individuals, all of whom lived in the suspected hotspots, including a 9 year old child. Our results provide field evidence that integrating LF surveillance with other surveys is effective and feasible for identifying potential hotspots, and conducting surveillance at worksites provides an efficient method of sampling large populations of adults.en_AU
dc.description.sponsorshipThe project was funded by grants from the Australian Institute of Tropical Health and Medicine (www.aithm.jcu.edu.au, #13122014) and the Faculty of Medicine and Biomedical Sciences at the University of Queensland (www.uq.edu.au, #2127835). CLL was supported by an Australian National Health and Medical Research Council (www.nhmrc.gov.au) Fellowship (1109035)en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn1935-2727en_AU
dc.identifier.urihttp://hdl.handle.net/1885/236774
dc.language.isoen_AUen_AU
dc.provenance© 2017 Lau et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_AU
dc.publisherPublic Library of Scienceen_AU
dc.relationhttp://purl.org/au-research/grants/nhmrc/1109035en_AU
dc.rights© 2017 Lau et al.en_AU
dc.rights.licenseCreative Commons Attribution Licenseen_AU
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_AU
dc.sourcePLoS Neglected Tropical Diseasesen_AU
dc.titleDetecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administrationen_AU
dc.typeJournal articleen_AU
dcterms.accessRightsOpen Accessen_AU
local.bibliographicCitation.issue9en_AU
local.bibliographicCitation.startpagee0005914en_AU
local.contributor.affiliationLau, Colleen, College of Health and Medicine, ANUen_AU
local.contributor.affiliationSheridan, Sarah, College of Health and Medicine, ANUen_AU
local.contributor.affiliationRyan, Stephanie, James Cook Universityen_AU
local.contributor.affiliationRoineau, Maureen, James Cook Universityen_AU
local.contributor.affiliationAndreosso, Athena, James Cook Universityen_AU
local.contributor.affiliationFuimaono, Saipale D, American Samoa Department of Healthen_AU
local.contributor.affiliationTufa, Joseph, American Samoa Department of Healthen_AU
local.contributor.affiliationGraves, Patricia, James Cook Universityen_AU
local.contributor.authoremailu5651486@anu.edu.auen_AU
local.contributor.authoruidLau, Colleen, u5651486en_AU
local.contributor.authoruidSheridan, Sarah, u4285944en_AU
local.description.notesImported from ARIESen_AU
local.identifier.absfor111700 - PUBLIC HEALTH AND HEALTH SERVICESen_AU
local.identifier.absfor111706 - Epidemiologyen_AU
local.identifier.ariespublicationu5684624xPUB219en_AU
local.identifier.citationvolume11en_AU
local.identifier.doi10.1371/journal.pntd.0005914en_AU
local.identifier.scopusID2-s2.0-85030652850
local.identifier.thomsonID000412142800054
local.identifier.uidSubmittedByu5684624en_AU
local.publisher.urlhttp://www.plosNTDS.org/en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Lau_Detecting_and_confirming_2017.pdf
Size:
2.23 MB
Format:
Adobe Portable Document Format